NEW YORK — UK diagnostics firm DnaNudge said on Tuesday that it has signed an exclusive distribution agreement for its PCR-based SARS-CoV-2 test and other genetic testing products in Spain with Quirónprevención.
Under the terms of the deal, Madrid-based Quirónprevención will offer DnaNudge's CovidNudge, a CE-IVD-marked point-of-care assay for SARS-CoV-2. Quirónprevención — a part of Spanish hospital group Quirónsalud — will also distribute DnaNudge's nutrition service, which uses an individual's genetic profile to make eating recommendations, and its upcoming skincare service.
Financial and other terms of the agreement were not disclosed.
Last month, DnaNudge raised $60 million in private financing.